Observational studyNutrients2024

Real-World Evaluation of Once-Weekly Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus in Spain (SEMA-RW Study).

Irene Caballero Mateos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.